Gilteritinib-d8
Gilteritinib-d8 is deuterium labeled Gilteritinib. Gilteritinib (ASP2215) is a potent and ATP-competitive FLT3/AXL inhibitor with IC50s of 0.29 nM/0.73 nM, respectively.
Product Specifications
CAS Number
2377109-74-3
Product Name Alternative
ASP2215-d8
UNSPSC
12352005
Target
FLT3; TAM Receptor
Type
Isotope-Labeled Compounds
Related Pathways
Protein Tyrosine Kinase/RTK
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Purity
98.0
Solubility
10 mM in DMSO|DMSO : 2mg/mL (ultrasonic) |Ethanol : 100mg/mL (ultrasonic; adjust pH to 2 with HCl)
Smiles
NC(C(C(NC1=CC(OC)=C(N2CCC(N3C([2H])([2H])C([2H])([2H])N(C([2H])([2H])C3([2H])[2H])C)CC2)C=C1)=N4)=NC(CC)=C4NC5CCOCC5)=O
Molecular Formula
C29H36D8N8O3
Molecular Weight
560.76
References & Citations
[1]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019;53 (2) :211-216.|[2]ASP2215, a novel FLT3/AXL inhibitor: Preclinical evaluation in acute myeloid leukemia (AML) . 2014 ASCO Annual Meeting.|[3]Mori M, et al. Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia. Invest New Drugs. 2017 Oct;35 (5) :556-565.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Isotope-Labeled Compounds
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
124062-ML750 100 µL
RNLS (Renalase, Monoamine Oxidase-C, MAO-C, C10orf59, FLJ11218) (MaxLight 750) discontinued
Sign In for Pricing
View Details